Cite
HARVARD Citation
Price, T. et al. (n.d.). 2110 Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). European journal of cancer. pp. S366-. [Online].